Immunotherapy of advanced renal cell carcinoma: Current and future therapies

References

• Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. The epidemiology of renal cell carcinoma. Eur Urol 2011; 60:615-21; PMID:21741761; http://dx.doi.org/10.1016/j.eururo.2011.06.049
   PubMed Web of Science ®Google Scholar
• Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treatment Rev 2008; 34:193-205; PMID:18313224; http://dx.doi.org/10.1016/j.ctrv.2007.12.001
   PubMed Web of Science ®Google Scholar
• Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urologic Clin N Am 1993; 20:303-21; PMID:8493752
   PubMed Web of Science ®Google Scholar
• Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J 2000; 6:S55.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Jama 1994; 271:907-13; PMID:8120958; http://dx.doi.org/10.1001/jama.1994.03510360033032
   PubMed Web of Science ®Google Scholar
• Fosså S. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27(2):187-93
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Eng J Med 1998; 338:1272-8; PMID:9562581; http://dx.doi.org/10.1056/NEJM199804303381805
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med 2007; 356:125-34; PMID:17215530; http://dx.doi.org/10.1056/NEJMoa060655
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28:2144-50; PMID:20368553; http://dx.doi.org/10.1200/JCO.2009.26.7849
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma. CALGB 90206. J Clin Oncol 2008; 26:5422-8; PMID:18936475; http://dx.doi.org/10.1200/JCO.2008.16.9847
   PubMed Web of Science ®Google Scholar
• Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncol 2010; 15:104-11; PMID:20061402; http://dx.doi.org/10.1634/theoncologist.2009-0250
   PubMedGoogle Scholar
• Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Eng J Med 2007; 356:2271-81; PMID:17538086; http://dx.doi.org/10.1056/NEJMoa066838
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 2010; 116:4256-65; PMID:20549832; http://dx.doi.org/10.1002/cncr.25219
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, et al. Cabozantinib vs. Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1814-23; PMID:26406150; http://dx.doi.org/10.1056/NEJMoa1510016
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Ren M, Dutcus C, Larkin J. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016; 17:e4-5; PMID:26758760; http://dx.doi.org/10.1016/S1470-2045(15)00543-4
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015; 16:1473-82; PMID:26482279; http://dx.doi.org/10.1016/S1470-2045(15)00290-9
   PubMed Web of Science ®Google Scholar
• De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol 2014; 15:e170-7; PMID:24694640; http://dx.doi.org/10.1016/S1470-2045(13)70569-2
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Eng J Med 2015; 373:1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338:1265-71; PMID:9562580; http://dx.doi.org/10.1056/NEJM199804303381804
   PubMed Web of Science ®Google Scholar
• Bedke J, Kruck S, Gakis G, Stenzl A, Goebell PJ. Checkpoint modulation–A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015; 11:1201-8; PMID:25912622; http://dx.doi.org/10.1080/21645515.2015.1016657
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 2007; 8:1142-8; PMID:18059313; http://dx.doi.org/10.1038/sj.embor.7401099
   PubMed Web of Science ®Google Scholar
• McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, et al. The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21:561-8; PMID:25424850; http://dx.doi.org/10.1158/1078-0432.CCR-14-1520
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-8; PMID:24907378; http://dx.doi.org/10.4049/jimmunol.1490019
   PubMed Web of Science ®Google Scholar
• Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982; 155:768-82; PMID:6801178; http://dx.doi.org/10.1084/jem.155.3.768
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169-77; PMID:16505437; http://dx.doi.org/10.1200/JCO.2005.03.6830
   PubMed Web of Science ®Google Scholar
• Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6:34-55; PMID:11161227; http://dx.doi.org/10.1634/theoncologist.6-1-34
   PubMed Web of Science ®Google Scholar
• Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14:2410-1; PMID:8708739
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113:293-301; PMID:18457330; http://dx.doi.org/10.1002/cncr.23552
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-32; PMID:12915604; http://dx.doi.org/10.1200/JCO.2003.02.122
   PubMed Web of Science ®Google Scholar
• Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, et al. Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). Cancer Immunology, Immunotherapy, 2016:1-9.
   Google Scholar
• Payne R, Glenn L, Hoen H, Richards B, Smith JW, 2nd, Lufkin R, Crocenzi TS, Urba WJ, Curti BD. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer 2014; 2:323-6; http://dx.doi.org/10.1186/2051-1426-2-13
   Google Scholar
• Negrier S, Caty A, Lesimple T, Douillard JY, Escudier B, Rossi JF, Viens P, Gomez F. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000; 18:4009-15; PMID:11118461
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34; PMID:17215530; http://dx.doi.org/10.1056/NEJMoa060655
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-81; PMID:17538086; http://dx.doi.org/10.1056/NEJMoa066838
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Escudier B. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007; 110:2468-77; PMID:17932908; http://dx.doi.org/10.1002/cncr.23056
   PubMed Web of Science ®Google Scholar
• Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 2002; 16:11-20; PMID:12469935
   PubMed Web of Science ®Google Scholar
• Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA. Induction of circulating tumor necrosis factor (TNF α) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8:426-36; PMID:3265420; http://dx.doi.org/10.1007/BF00916947
   PubMed Web of Science ®Google Scholar
• Numerof RP, Aronson FR, Mier JW. IL-2 stimulates the production of IL-1 α and IL-1 β by human peripheral blood mononuclear cells. J Immunol 1988; 141:4250-7; PMID:3143761
   PubMed Web of Science ®Google Scholar
• Hotte S, Waldron T, Canil C, Winquist E. Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. Can Urol Assoc J 2007; 1:27-38; PMID:18542758
   PubMedGoogle Scholar
• Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-α. Semin Oncol 1998; 25:3-8; PMID:9482534
   PubMed Web of Science ®Google Scholar
• Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065-8; PMID:1335362; http://dx.doi.org/10.1016/S0092-8674(05)80055-8
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
   PubMed Web of Science ®Google Scholar
• Hiraoka N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol 2010; 15:544-51; PMID:20924634; http://dx.doi.org/10.1007/s10147-010-0130-1
   PubMed Web of Science ®Google Scholar
• Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1:793-801; PMID:7534620; http://dx.doi.org/10.1016/S1074-7613(94)80021-9
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011
   PubMed Web of Science ®Google Scholar
• McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fass∫ M, Wang YV, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol JCO637421, 2016; 34(8):833-42; PMID:26755520; http://dx.doi.org/10.1200/JCO.2015.63.7421
   PubMed Web of Science ®Google Scholar
• Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (Hagerstown, Md.: 1997) 2007; 30:825; PMID:18049334; http://dx.doi.org/10.1097/CJI.0b013e318156e47e
   PubMed Web of Science ®Google Scholar
• Gangadhar TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Luke JJ, Balmanoukian AS, Kaufman DR, Zhao Y, Maleski J, et al. Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. Journal for Immunotherapy of Cancer, 2015; 3(2):1.
   Google Scholar
• Dudek AZ, Sica RA, Sidani A, Jha GG, Xie H, Shivaram Alva A, Stein MN, Singer EA. Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003. ASCO Annual Meeting Proceedings, 2016; 34(Supp 2):559.
   Google Scholar
• Atkins MB, Choueiri TK, Hodi FS, Thompson JA, Hwu WJ, McDermott DF, Brookes M, Tosolini A, Ebbinghaus S, Yang Z, et al. Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. ASCO Annual Meeting Proceedings 2015; 33(Supp 15):3009.
   Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7; PMID:22614989; http://dx.doi.org/10.1200/JCO.2012.41.6750
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Eng J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Weber JS, Antonia SJ, Topalian SL, Schadendorf D, Larkin JMG, Sznol M, Liu HY, Waxman I, Robert C. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. ASCO Annual Meeting Proceedings 2015; 33(Supp 15):9018.
   Google Scholar
• Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 60:8448.
   Google Scholar
• Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, McDermott DF, Delord J-P, Rhee IP, Mokatrin A, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings, 2013; 31(Supp 15):4505.
   Google Scholar
• Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 2011; 104:399-406; PMID:21285971; http://dx.doi.org/10.1038/sj.bjc.6606084
   PubMed Web of Science ®Google Scholar
• Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH, Jr, Karsh LI, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer 2015; 3:14; PMID:25901286; http://dx.doi.org/10.1186/s40425-015-0055-3
   PubMed Web of Science ®Google Scholar
• Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, Palucka AK. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003; 987:180-7; PMID:12727638; http://dx.doi.org/10.1111/j.1749-6632.2003.tb06047.x
   PubMed Web of Science ®Google Scholar
• Porta C, Bonomi L, Lillaz B, Paglino C, Rovati B, Imarisio I, Morbini P, Villa C, Danova M, Mensi M, et al. Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res 2007; 27:165-73; PMID:17352228
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 2007; 56:271-85; PMID:16819631; http://dx.doi.org/10.1007/s00262-006-0194-y
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794-9; PMID:19826129; http://dx.doi.org/10.1200/JCO.2008.21.4809
   PubMed Web of Science ®Google Scholar
• Rini BI, Eisen T, Stenzl A, Brugger W, Weinschenk T, Mahr A, Fritsche J, Hilf N, Mendrzyk R, Lindner J, Schmid A,...Reinhardt C. IMA901 multipeptide vaccine randomized international phase III trial (IMPRINT): A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. ASCO Annual Meeting Proceedings 2011; 29(Supp 15):TPS183.
   Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci 2010; 107:4275-80; http://dx.doi.org/10.1073/pnas.0915174107
   PubMed Web of Science ®Google Scholar
• Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25Hi regulatory T cells. Int Immunol 2009; 21(9):1065-77.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25; PMID:19581407; http://dx.doi.org/10.1084/jem.20082492
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Hammers HJ, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Razak ARA, Kumar Pal S, Henner Voss M, Sharma P, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (MRCC). Annals of Oncology 2015; 25(suppl 4):iv361-iv362.
   Google Scholar
• Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332
   PubMed Web of Science ®Google Scholar
• Edwards JP, Emens LA. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE 2 in murine macrophages. Int Immunopharmacol 2010; 10:1220-8; PMID:20637838; http://dx.doi.org/10.1016/j.intimp.2010.07.002
   PubMed Web of Science ®Google Scholar
• Sznol M, McDermott DF, Jones SF, Mier JW, Waterkamp D, Rossi C, Wallin J, Funke RP, Bendell JC. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings 2015; 33(Supp 7):410.
   Google Scholar
• Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Knox JJ, Kumar Pal A, Henner Voss M, Sharma P, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings 2014; 32(Supp 15):5010.
   Google Scholar
• Atkins MB, Gupta S, Choueiri TK, McDermott DF, Puzanov I, Tarazi J, Keefe S, Rosbrook B, Chakrabarti D, Plimack ER. Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma. J Immunotherapy of Cancer 2015; 3(Suppl 2):1.
   Google Scholar
• Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Hutson A, Piekarz R, et al. Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose Interleukin 2 in renal cell carcinoma patients (CTEP# 7870). ASCO Annual Meeting Proceedings 2016; 34(Supp 2):500.
   Google Scholar
• Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, Kim H, Lee H. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. J Transl Med 2011; 9:178; PMID:22013914; http://dx.doi.org/10.1186/1479-5876-9-178
   PubMed Web of Science ®Google Scholar
• Bowen RC, Meek S, Williams M, Grossmann KF, Andtbacka RHI, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Holmen SL, et al. A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma. ASCO Annual Meeting Proceedings, 2015; 33(Supp 15):3018.
   Google Scholar
• Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 2012; 10:169; PMID:22909342; http://dx.doi.org/10.1186/1479-5876-10-169
   PubMed Web of Science ®Google Scholar
• Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, et al. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother 2013; 36:490-5; PMID:24145360; http://dx.doi.org/10.1097/CJI.0000000000000003
   PubMed Web of Science ®Google Scholar